Vaxcyte, Inc. (PCVX)

How it makes money

There is no revenue model in operation. The 10-K states plainly that the company has no products approved for commercial sale and no source of product revenue, and the FY2025 results report no revenue line at all. Everything the company spends is funded by money raised from investors: it ended 2025 with $2.44 billion of cash and investments, down from $3.13 billion a year earlier, and raised roughly a further $600 million in an equity offering in February 2026. For a beginner the important consequence is that the share price is not a claim on sales or profits — there are none — but on the chance that a candidate is approved and sold years from now, and each year of trials is paid for by issuing new shares, which dilutes existing holders. If VAX-31 is ever approved, the intended model would be the ordinary vaccine one: sell doses to governments, national immunisation programmes, insurers and large purchasers, with volumes driven by official vaccination recommendations. That model is a plan, not a business the filing can show.

A moat protects profits, and Vaxcyte has no profits and no sales to protect, so the honest reading is that no durable competitive advantage exists today. What it does have are assets that could become one: patents and licensed rights around the XpressCF cell-free synthesis platform, trial data, and a manufacturing suite reserved at Lonza. None of these is proven to keep a rival out. The 10-K itself says the company competes against firms with significantly greater resources and experience — Pfizer, whose Prevnar franchise is the incumbent standard, Merck and GSK — and lists both the failure to obtain and maintain patent protection and the possibility of being outpaced by better-resourced competitors among its risk factors. The platform is also described in the filing as novel and unproven, which cuts the other way from a moat: an approach nobody else uses is not automatically an approach that works.

Two different things move here, and it helps to keep them apart. The end market Vaxcyte is aiming at is defensive: pneumococcal vaccination is driven by official immunisation schedules for infants and older adults, paid largely by public programmes and insurers, and a recession does not stop a child's vaccination calendar. Demand is set by recommendation bodies and birth and ageing cohorts, not by the economic cycle. The company's own fortunes, however, do not yet touch that market at all. Having no sales, Vaxcyte lives on capital raised from investors, and the availability of that capital is highly cyclical — biotech funding windows open and close with sentiment and interest rates. The filing's own warning that additional funding may not be available on acceptable terms is exactly this exposure.

Key risks

• Everything depends on the pneumococcal franchise — The company states it is highly dependent on the success of its pneumococcal conjugate vaccine candidates. VAX-31 carries the weight of the whole business; a disappointing Phase 3 readout would not be one setback among many but the central one.
• Clinical-stage company with a limited operating history — The candidates are in clinical or preclinical stages and the company has a limited operating history. There is no track record of taking a product from laboratory to market to judge it by.
• Persistent losses, no profitability in sight — The filing reports significant net losses since inception and does not expect profitability in the near term. The FY2025 loss was $766.6 million and grew from $463.9 million the year before.
• Need for further funding on terms that may not be available — Substantial additional funding is required to finance operations, and the company warns it may not be available on acceptable terms. Cash fell by roughly $690 million during 2025 alone.
• A novel and unproven technology — The cell-free protein synthesis approach is described as creating unforeseen risks and making development unpredictable. No vaccine built this way has yet been approved.
• Trials may fail or slip — Candidates may fail in development or suffer delays that materially affect their commercial viability. Delay is itself costly here, because the burn continues while the cash clock runs.
• Regulators may disagree — The FDA may disagree with the regulatory plan and deny approval; the approval process is described as lengthy and time-consuming, and the operational capacity and resource levels of regulatory authorities may fluctuate.
• Competitors with far greater resources — The company competes against firms with significantly greater resources and experience, which could outpace its development efforts. Pfizer, Merck and GSK are the established players in pneumococcal vaccines.
• Dependence on third-party manufacturing — The company relies on third-party manufacturing and supply partners, and disruptions would materially and adversely affect the business. It also warns it may be unable to scale production, which would harm commercialisation prospects.
• Intellectual property may not hold — The company may fail to obtain and maintain patent protection for its candidates and platform, or face infringement claims from others.
• Key people — The filing cites difficulty hiring and retaining key personnel as a risk. In a company whose only assets are science and trial execution, this is not a minor item.

There are no customers to concentrate. The company has no products approved for commercial sale and no source of product revenue, so the filing discloses no customer concentration figure. Worth noting for the future: if a PCV reaches market, the vaccine business is structurally concentrated on the buying side — national immunisation programmes, government agencies and a small number of large distributors and insurers account for most volume — so concentration would become a real question the day sales begin, not before.